.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Accenture
Moodys
QuintilesIMS
Teva
Julphar
Mallinckrodt
Covington
McKesson
Johnson and Johnson

Generated: November 22, 2017

DrugPatentWatch Database Preview

Atazanavir sulfate; cobicistat - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for atazanavir sulfate; cobicistat and what is the scope of atazanavir sulfate; cobicistat freedom to operate?

Atazanavir sulfate; cobicistat
is the generic ingredient in one branded drug marketed by Bristol-myers Squibb and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atazanavir sulfate; cobicistat has two hundred and fifty-nine patent family members in forty-eight countries and thirty-three supplementary protection certificates in twelve countries.

There are twenty-three drug master file entries for atazanavir sulfate; cobicistat. One supplier is listed for this compound.

Summary for atazanavir sulfate; cobicistat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: atazanavir sulfate; cobicistat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,939,553Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,383,655Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,486,942Modulators of pharmacokinetic properties of therapeutics► Subscribe
6,166,004 Combinations of HIV protease inhibitors with reverse transcriptase inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
6,300,519 Antivirally active heterocyclic azahexane derivatives► Subscribe
9,139,541Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,088,770Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,067,449Modulators of pharmacokinetic properties of therapeutics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: atazanavir sulfate; cobicistat

Country Document Number Estimated Expiration
Australia2008275744► Subscribe
Denmark2487166► Subscribe
South Korea20100040896► Subscribe
Portugal2487166► Subscribe
European Patent Office2487168► Subscribe
Japan5393665► Subscribe
Japan6147282► Subscribe
Spain2603645► Subscribe
CroatiaP20161476► Subscribe
South Korea20140004808► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ATAZANAVIR SULFATE; COBICISTAT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
864Luxembourg► SubscribePRODUCT NAME: COBICISTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; FIRST REGISTRATION DATE: 20130527
2015040Lithuania► SubscribePRODUCT NAME: COBICISTATUM; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524
C023/2005Ireland► SubscribeSPC023/2005, 20060612, EXPIRES: 20190301
2015 00060Denmark► SubscribePRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527
189Luxembourg► Subscribe91189, EXPIRES: 20190302
0860Netherlands► SubscribePRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN TENOFOVIR-ALAFENAMIDE, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIR-ALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1061 20151123
2 5024-2015Slovakia► SubscribePRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/13/830 20130527
0203Netherlands► Subscribe300203, 20170414, EXPIRES: 20190301
2016000120Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713
2016000104Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Queensland Health
Julphar
US Department of Justice
Novartis
Cipla
Harvard Business School
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot